ARIAD Pharmaceuticals (ARIA)
News
| 6:58 AM | $ARIA insiders 250,000 shares + - a few in last 30 days.. dont think that is something to worry about, meanwhile fidelity has 23.5 million by markf |
| May 26 | $ARIA will be hard to figure. We all know if 6/4 ASCO presentation is (+) stock will pop, but don't know if gen public has alrdy digested... by nick159 |
| May 26 | NEW POST: NEXT WEEK WILL BE OFF THE CHART HUGE http://stks.co/3zsj $AAPL, $SPX, $ARIA, $IBB, $QQQ by upsidetrader |
| May 25 | shouldn't insiders be holding if they had confidence in ASCO? never seen this much selling in my life lol http://stks.co/3zEF $ARIA by johnkelly |
| May 24 | $ARIA Whats the consensus on how big can ARIA possibly pop on 6/5? by Jollygreen84 |
| May 23 | http://stks.co/3xkr wow got even MORE $ARIA insider selling monday! insiders keep selling, investors keep buying lol by johnkelly |
| May 23 | $ARIA up .20 by markf |
| May 21 | @RickPalmer907 @kokoluck $ARNA I meant to mention that if you check out $VVUS and $ARIA today, they had large, 4 p.m. double trades by SlownSteady |
| May 21 | $ARNA $ARIA $GALE gl everybody. by nick159 |
| May 21 | $ARIA my bad...the street.com has FDA date as June 5th. by nick159 |
| May 21 | Here's What Smart Billionaire George Soros Is Buying and Selling Fool |
| May 17 | Biotech-Focused Baker Bros. $3.7B Fund Bought These 3 Big Winners And Sold Others In ... |
| May 17 | Ariad Pharmaceuticals, ArQule, Exelixis, Aveo, Other Cancer Drug Stocks Fall |
| May 17 | ARIAD PHARMACEUTICALS INC Financials |
| May 17 | Today's Bio Pharma ASCO Abstracts |
Profile
Exchange: NASDAQGM Sector: Healthcare Industry: Biotechnology
ARIAD Pharmaceuticals, Inc. is a small pharmaceutical company focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. It has three products: Ridaforolimus, Ponatinib and AP26113. Its approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant and difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. The company is located in Cambridge, Massachusetts. It was established in 1991 by Larry Bock, David Blech and Harvery Berger. It has strong partnerships with Merck.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). ARIAD Pharmaceuticals is up 90.35% over the last year vs S&P 500 Total Return up 1.62%, Seattle Genetics up 5.38%, and Sunesis Pharmaceuticals down 3.52%.
- ARIA Total Returns
- ^SPXTR Total Returns
- SGEN Total Returns
- SNSS Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these ARIA related companies
Pro Strategies Featuring ARIA
Did ARIAD Pharmaceuticals make it into our Pro Portfolio Strategies?
ARIA Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other ARIA Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ARIA | 16.77 | -0.08 | -0.47% | 2.665B |
| ARI | 15.89 | -0.12 | -0.75% | 326.70M |
| ARGN | 12.21 | -0.32 | -2.55% | 352.26M |
| ARG | 87.77 | -0.96 | -1.08% | 6.702B |
| AREX | 28.34 | -0.15 | -0.53% | 944.01M |
| ARE | 69.83 | -0.69 | -0.98% | 4.332B |
| ARDNA | 81.80 | +0.80 | +0.99% | 251.13M |
| ANV | 27.47 | -0.20 | -0.72% | 2.463B |
| ANTP | 2.460 | -0.00 | -0.04% | 5.880M |
| ANTH | 1.85 | -0.06 | -3.14% | 75.83M |
